

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



PRELIMINARY PROGRAMME – MAIN TRACK

Friday, 25 September 2026

13:00-13:45	Registration & Welcome Coffee	
13:45-14:00	Welcome from the organisers Maria Ester Bernardo (IT), Claire Booth (UK) and Tayfun Güngör (CH)	
14:00-16:07	Session 1 Allogeneic HSCT and HSC-GT for IEM Chairs: Giulia Consiglieri (IT) and Robert Wynn (UK)	
14:00-14:07	Case presentation: Disseminated Mycobacterium avium complex infection and Immune Reconstitution Inflammatory Syndrome following Haematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Type II: a complex post-transplant course	Aisling McCann (IE)
14:07-14:27	Biomarkers in ALD, Gene Therapy and Allo-HCT	Troy Lund (US)
14:27-14:47	Biomarkers on CSF in MLD	Valeria Calbi (IT)
14:47-15:02	Update on the MPS II clinical trial/immune response to transgene and assays	Robert Wynn (UK)
15:02-15:17	Update on the MPS III clinical trial	Robert Wynn (UK)
15:17-15:32	Real-world data for MLD	Valeria Calbi (IT)
15:32-15:47	Platform approach for LSDs with skeletal and neurological involvement: clinical trial design	Maria Ester Bernardo (IT)
15:47-16:07	Mechanisms of immune response after HSC-GT for metabolic diseases	Silvia Gregori (IT)
16:10-16:40	Coffee Break	
16:40-18:50	Session 2 CGD special session from mechanism to novel therapies Chairs: Tayfun Güngör (CH) and Emma Morris (UK)	
16:40-16:47	Case presentation: Chronic Granulomatous Disease: a Cohort of 173 Patients—10-Years Single Center Experience from Egypt	Sohilla Lotfy (EG)
16:47-17:12	EROS and new insights into CGD signaling pathways	David Thomas (UK)
17:12-17:32	CGD - a tough candidate for allo HSCT	Tayfun Güngör (CH)
17:32-17:52	Biologics of chronic granulomatous disease	Jennifer Leiding (US)
17:52-18:07	Gene Therapy in HSC for correcting the oxidative burst in CGD	Giorgia Santilli (UK)
18:07-18:17	The complexities of surviving CGD	Helen Braggins (UK)
18:17-18:27	First inhuman in vivo gene therapy	Emma Morris (UK)
18:27-18:40	Panel Discussion	
18:40-18:50	Tribute to Paul Veys	Persis Amrolia (UK)

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



PRELIMINARY PROGRAMME – NURSES TRACK

Saturday, 26 September 2026

10:30-12:30	Session 1 Care Team Challenges in Patient and Family Care Chairs: Marina Ben Izhak (IL) and Karen Nicholson (UK) Welcome message	
10:30-11:00	Challenges we face every day treating private and international patients	Tanja Stankova (UK)
11:00-11:30	Stakeholder perspectives on Stem Cell Therapy for Patients with Inborn Errors of Immunity (25+5)	Hilda Mekelenkamp (NL)
11:30-12:00	Partnering with Families: Co-Designing information resources for paediatric Gene Therapy	Evey Howley (UK)
12:00-12:30	Psycho-educational intervention for parents after their child was diagnosed with an IEI following a positive NBS test	Patricia Luck (CH)
12:30-13:00	Lunch Break	
13:00-14:15	Session 5 Thymus transplant (Main Track)	
14:15-15:15	Session 6 Advances in GvHD and endothelial complications (Main Track)	
15:15-15:45	Coffee Break	
15:45-16:45	Session 2 Quality of Life and long-term outcomes Chairs: Evey Howley (UK) and Tanja Stankova (UK) Welcome message	
15:45-16:05	Post-GT experience in WAS patients with a focus on quality of life and long-term follow-up	Federico Fraschetta (IT)
16:05-16:25	Developing a pathway for transition from the paediatric to adult long-term follow-up clinic	Karen Nicholson (UK)
16:25-16:45	Back to Life: A Multidisciplinary Clinic for Pediatric Post-BMT Care	Marina Ben Izhak (IL)

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



PRELIMINARY PROGRAMME – MAIN TRACK

Saturday, 26 September 2026

09:00-09:15	ADA2 updates, including management of patients with dominant negative disease	Isabelle Meyts (BE)
09:15-10:30	Session 3 HSC-Gene therapy for IEIs Chairs: Sung-Yun Pai (US) and Francesca Ferrua (IT)	
09:15-09:25	Overview of current open trials	Claire Booth (UK)
09:25-09:35	Preclinical development of gene therapy for Major Histocompatibility Complex Class II (MHC II) Deficiency	Alessandra Magnani (ES)
09:35-09:40	International XIAP GT consortium	Claire Booth (UK)
09:40-09:50	CD40L moving to the clinic	Daniele Canarutto (IT)
09:50-10:00	P47 CGD LV clinical trial update	Jasmeen Dara (UK)
10:00-10:10	Artemis -SCID	Marina Cavazzana (FR)
10:10-10:20	WASKYRA approval - current update about rollout/availability and results of EAS	Francesca Ferrua (IT)
10:20-10:30	Initiatives and regulatory innovation to improve access to GT in Europe	Arjan Lankester (NL)
10:30-10:45	Coffee Break	
10:45-11:25	Keynote Lecture Epstein-Barr Virus, autoimmune disease & big data management	Prof. Christian Münz (CH)
11:25-12:10	Session 4 B cells and plasma cell derived treatments Chairs: Carsten Speckmann (DE) and Julian Thalhammer (DE)	
11:25-11:35	Pathology on early B cells defects	Mirjam van der Burg (NL)
11:35-11:45	HSCT experience in XLA	Andrew Gennery (UK)
11:45-11:55	B cell pathology in CVID	Bärbel Keller (DE)
11:55-12:10	Anti-CD19 CAR T cells refractory autoimmune disease	Franco Locatelli (IT)
12:10-13:00	Lunch Break	
13:00-14:22	Session 5 Thymus transplant Chairs: Alexandra Kreins (UK) and Mathias Hauri-Hohl (CH)	
13:00-13:07	Case presentation: Delayed thymic immune reconstitution in paediatric patients with Chronic Granulomatous Disease that underwent allogeneic hematopoietic stem cell transplantation	Laura Marsiglio (CH)
13:07-13:27	Rebuilding Immunity after Paediatric HCT: The Role of Thymic Hormones	Coco de Koning (NL)
13:27-13:47	Sex differences in the human thymus	Viktoria Hennings (SE)
13:47-14:07	Two cases on Challenging referrals for thymic transplants	Tania Masmias (DK) and Zainab Golwala (UK)
14:07-14:22	Discussions on the current state algorithm for decision-making	Alexandra Kreins (UK)

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



PRELIMINARY PROGRAMME – MAIN TRACK

Saturday, 26 September 2026

14:22-15:24	Session 6 Advances in endothelial complications	
	Chairs: Andrew Gennery (UK) and Virginia Meda Spaccamela (CH)	
14:22-14:29	Case presentation: Impact of Pulmonary Disease on Survival and Long-Term Respiratory Outcomes in Children undergoing Haematopoietic Cell Transplantation for Inborn Errors of Immunity	Ho Wai Koo (MY)
14:29-14:39	Light Therapy for oral mucositis: the nurse experience	Karin Schoch (CH) & Svenja Schweizer (CH)
14:39-14:54	Endothelial biomarker dynamics in Sinusoidal Obstruction Syndrome following paediatric allogeneic HSCT	Katrine Kielsen (DK)
14:54-15:09	Paediatric VOD: Still a concern?	Matthias Felber (CH)
15:09-15:24	Pulmonary Vasculopathy after paediatric HSCT - a review of the disease and proposal for a monitoring strategy and early treatment	Antonio Grasso (UK)
15:25-15:45	Coffee Break	
15:45-16:25	Keynote Lecture	
	Immuno-conditioning for SCT and GT	Prof. Markus Manz (CH)
16:25-17:17	Session 7 Precision conditioning	
	Chairs: Thomas Fox (UK) and Arjan Lankester (NL)	
16:25-16:32	Case presentation: Comparison of Cyclophosphamide and Fludarabine in alloreactive settings in vitro	Antonia Reers (DE)
16:32-16:47	Advances in targeted conditioning	Persis Amrolia (UK)
16:47-17:02	PK and model-informed precision dosing of chemotherapy to optimize conditioning	Janel Long-Boyle (US)
17:02-17:17	Alemtuzumab PK/PD to optimize conditioning	Thibaut César (FR)
17:17-18:24	Session 8 Advanced diagnostics and treatment of infections	
	Chairs: Bénédicte Neven (FR) and Jacques Rivière (ES)	
17:17-17:24	Case presentation: Successful Allogeneic HSCT Following Peri-Transplant IFN-γ Blockade With Emapalumab in Complete IFNGR2 Deficiency	Linda Rossini (IT)
17:24-17:44	Fungal infections in CGD: new antifungal drugs, indications for granulocyte transfusions as bridge to HSCT, when to transplant with an active fungal infection	Christa Zerbe (US)
17:44-17:59	When conventional antimicrobials are not enough: new antimicrobial drugs in HSCT, including antibacterials, antivirals (anti-HSV agents) and phage therapy	Natalia Mendoza (ES)
17:59-18:14	Atypical viral infections: Aichi virus	Muriel Schmutz (FR)
18:14-18:24	NGS case report with neurological involvement, case series from Necker's experience with NGS	Cassandre Cremades (FR)

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



PRELIMINARY PROGRAMME – MAIN TRACK

Sunday, 27 September 2026

09:00-10:30	Session 9 Juniors session Management of IEIs in cases with unclear/inconclusive genetic findings Chairs: Lisa Ott de Bruin (NL) and Sujal Ghosh (DE)	
09:00-09:20	Transplant decision-making in severe T cell immunodeficiency	Sophie Hambleton (UK)
09:20-09:27	Case 1	Filippo Consonni (IT)
09:27-09:34	Case 2	Lisa Ott de Bruin (NL)
09:34-09:41	Case 3	Alexandra Kreins (UK)
09:41-10:30	Panel Discussion	
10:30-10:50	Coffee Break	
10:50-11:35	Session 10 IEWP Studies Chairs: Maria Ester Bernardo (IT) and Claire Booth (UK)	
10:50-11:00	DADA2 study	Juliana Silva (UK)
11:00-11:15	P-CID study	Stephan Ehl (DE)
11:15-11:25	FHL2/3 study	Svea Böhm (DE)
11:25-11:35	CHH study	Helja Lång (FI)
11:35-12:50	Session 11 Advances in immune dysregulation Chairs: Tiphaine Arlabosse (CH) and Jana Pachlopnik Schmid (CH)	
11:35-11:42	Case presentation: First haematopoietic cell transplantation as a curative treatment for monogenic SFK-related multisystem vasculitis	Ina Schim van der Loeff (UK)
11:42-11:59	Autophagy/inflammation in WAS	Elizabeth Rivers (UK)
11:59-12:16	STAT6 GOF updates on the current ESID registry study	Julia Körholz (DE)
12:16-12:33	ZNFX1 update on current collaborative study	Julius Köppen (CH)
12:33-12:50	NFKBIA clinical spectrum and HSCT strategies	Winnie Ip (UK)
12:50-13:00	Final Remarks Maria Ester Bernardo (IT), Claire Booth (UK) and Tayfun Güngör (CH)	